Description

The overall aim of Liqbiopsens project is the further development and validation in real settings of a novel diagnostic platform for the early and fast detection of ctDNA and their KRAS and BRAF mutations associated to colorectal cancer through blood samples.

See our Description Brochure

The main features of Liqbiopsens are:

  • reliability (detection rates vary from 95–100 %),
  • low-cost (40-50 € per sample analysis), sensitivity (in the zM range),
  • multiplexing capabilities (analysis of 27 KRAS and BRAF mutations simultaneously),
  • short analysis time (30-60 min.),
  • user-friendly interface and
  • flexibility.

Solution proposed by the Liqbiopsens project relies on the multidisciplinary integration of different Key Enabled Technologies: microelectronics, microfluidics, nanomaterials and genomics. In particular, Liqbiopsens platform is based on the integration of two novel complementary technologies. On the one hand, the revolutionary DGL© technology property of DestiNA Genomics Ltd, capable of delivering faster, more error-free detection of nucleic acids and their mutations than current enzyme-based detection systems, making 'false positive' results a thing of the past. On the other hand, a novel high resolution acoustic wave microsensor technology property of AWSensors, that allows an accurate, inexpensive, label-free, direct and real time transduction method to quantitatively evaluate the results of the application of the above mentioned DGL© technique. 

..

RSS de esta página
Advance Wave Sensors SL
Destina Genomics Ltd.
Foundation for Research & Technology - Hellas
Servicio Andaluz de Salud - Hospital Universitario San Cecilio Granada
Sistemas Genómicos SL
Université Catholique de Louvain - ICTEAM
Co-funded by the Horizon 2020 Framework Programme of the European Union